

## Ibrance® (palbociclib) - Updated label

- On December 13, 2022, the <u>FDA approved</u> Pfizer's <u>Ibrance (palbociclib)</u>, for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.
  - Ibrance was previously approved for this use in postmenopausal women or in men. The indication was updated to include pre-/perimenopausal women.
- Ibrance is also approved for the treatment of adult patients with HR-positive, HER2-negative
  advanced or metastatic breast cancer in combination with fulvestrant in patients with disease
  progression following endocrine therapy.
- The recommended dose of Ibrance is a 125 mg tablet or capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days.
- Pre/perimenopausal women treated with the combination Ibrance plus an aromatase inhibitor or fulvestrant therapy should also be treated with luteinizing hormone-releasing hormone agonists according to current clinical practice standards.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.